News & Events
-
Dr.Yanagiya from ARCALIS will present a poster and serve as session chair at the TIDES ASIA 2024
-
ARCALIS, Inc. Attending at CPHI Japan 2024
-
Announcement of Website Renewal
-
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics
-
Meiji Seika Pharma Receives Manufacturing and Marketing Approval of “ARCT-154”, Self-Amplifying mRNA Vaccine against COVID-19, from MHLW in Japan
-
ARCALIS will be exhibiting at the 11th International mRNA Health Conference.
-
Dr. Drew Weissman, a member of Arcturus Therapeutics’ Scientific Advisory Board, Received 2023 Nobel Prize in Physiology or Medicine
-
The Construction Plan of mRNA Therapeutics Manufacturing, Technology Development Facility has been Selected for the METI Subsidy Programs
-
Notice of Completion of New mRNA Drug Substance Plant
-
Notice of ARCALIS’ Head Office Relocation
-
ARCALIS exhibit at the 3rd Annual mRNA-Based Therapeutics Summit
-
ARCALIS Renews the Corporate Logo design
-
Meiji Seika Pharma Submitted an Additional Application for Booster Dose of ARCT-154 in Japan
-
Thursday, June 15, our scientist will give a presentation on a webinar related to mRNA therapeutics, hosted by Roche Diagnostics
-
Notice Concerning Change of Representative Directors
-
ARCALIS and Hitachi Enter Joint Research Agreement on mRNA Sequence Design Technology
-
Meiji Seika Pharma Submitted New Drug Application to Manufacture and Market ARCT-154 in Japan
-
Meiji Seika Pharma Announces that it has entered into an Alliance Agreement for Distribution and Sales of ARCT-154 with CSL Seqirus. Domestic manufacturing system will be promoted by ARCALIS’ mRNA drug manufacturing facility.
-
Meiji Seika Pharma started the Phase III Trial of “ARCT-154”
-
Arcturus Therapeutics Announces Strategic collaboration with CSL
-
Industry Minister Nishimura visits ARCALIS Minami-soma Plant
-
【EVENT】ARCALIS will join the 10th International mRNA Health Conference to introduce our Integrated Drug Discovery Service and CMC development support services.
-
Construction plan of mRNA therapeutics and vaccine production facility has been adopted for “Biopharmaceutical Production Base Development Project for Strengthening the Vaccine Production System” by the Ministry of Economy, Trade and Industry
-
ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics
-
Official Website Launch of ARCALIS Inc.
-
Axcelead Decided to Build an mRNA Drug Manufacturing Plant in Minamisoma City, Fukushima Prefecture
-
Axcelead Launches ARCALIS, a Joint Venture to Manufacture mRNA Therapeutics